

# Bringing International Vaccine Development Expertise to Nigeria through Partnerships and Tech Transfer



## Novel HIV VLP Based Vaccine

Induced broadly Neutralizing antibodies in Mice model

## Novel Ebola VLP Based Vaccine

Highly immunogenic in mice model. Plans are underway to developed a bivalent VLP Ebola

## Novel Cell-based Yellow Fever Vaccine

Licensed a novel cell based YF vaccine - combines characteristics of DNA and inactivated vaccines. The IDNA YF vaccine induced high neutralizing antibodies in mice. Can be formulated for storage at RT.

## Novel Reassortant Lassa Vaccine

Licensed a Lassa Candidate Vaccine based on reassortant technology. GMP material is now available for tox study and clinical trials.

## Novel HPV Vaccine

Developing a trivalent 16,18 and 35 HPV vaccine based on African HPV serotypes. Could protect over 90% of HPV serotypes circulating in Africa based on cross-protections

### Partners:

Merck KGaA, MilliporeSigma, Technovax LLC, Medigen LLC., Lion's Head UK, Afreximbank Cairo, FinaBio, ITC Geneva, Bharat Biotech India, Walvax etc